Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-003382-17
    Sponsor's Protocol Code Number:MK-1439A-021
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-07-02
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-003382-17
    A.3Full title of the trial
    A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA? Once-Daily in Treatment-Naïve HIV-1 Infected Subjects
    Ensayo clínico de fase III multicéntrico, doble ciego, aleatorizado, controlado con producto activo para evaluar la seguridad y eficacia de MK-1439A administrado una vez al día frente a ATRIPLA? administrado una vez al día en sujetos infectados por el VIH-1 sin tratamiento previo
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    MK-1439A once a day versus ATRIPLA once a day in treatment-naïve HIV-1 infected subjects
    K-1439A administrado una vez al día frente a ATRIPLA administrado una vez al día en sujetos infectados por el VIH-1 sin tratamiento previo
    A.3.2Name or abbreviated title of the trial where available
    MK-1439A versus ATRIPLA in treatment-naïve HIV-1 infected subjects
    K-1439A frente a ATRIPLA en sujetos infectados por el VIH-1 sin tratamiento previo
    A.4.1Sponsor's protocol code numberMK-1439A-021
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02403674
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMerck Sharp & Dohme de España S.A.
    B.5.2Functional name of contact pointInvestigación Clínica
    B.5.3 Address:
    B.5.3.1Street AddressC/ Josefa Valcárcel, 38
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28027
    B.5.3.4CountrySpain
    B.5.4Telephone number+34913210600
    B.5.5Fax number+34913210590
    B.5.6E-mailensayos_clinicos@merck.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMK-1439A
    D.3.2Product code MK-1439A
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLAMIVUDINE
    D.3.9.1CAS number 134678-17-4
    D.3.9.4EV Substance CodeSUB08392MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTENOFOVIR DISOPROXIL FUMARATE
    D.3.9.1CAS number 202138-50-9
    D.3.9.4EV Substance CodeSUB12607MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNdoravirine
    D.3.9.3Other descriptive nameMK-1439
    D.3.9.4EV Substance CodeSUB107739
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ATRIPLA
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb and Gilead Sciences Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameATRIPLA
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNefavirenz
    D.3.9.3Other descriptive nameEFAVIRENZ
    D.3.9.4EV Substance CodeSUB06463MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number600
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEMTRICITABINE
    D.3.9.1CAS number 143491-57-0
    D.3.9.4EV Substance CodeSUB01882MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTENOFOVIR DISOPROXIL FUMARATE
    D.3.9.1CAS number 202138-50-9
    D.3.9.4EV Substance CodeSUB12607MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Human Immunodeficiency Virus-1 infection
    virus de la inmunodeficiencia humana de tipo 1
    E.1.1.1Medical condition in easily understood language
    HIV infection
    Infección por VIH
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level LLT
    E.1.2Classification code 10068341
    E.1.2Term HIV-1 infection
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1) To evaluate the non-inferior antiretroviral activity of MK-1439A q.d. compared to ATRIPLA q.d. as measured by the proportion of subjects achieving HIV-1 RNA <50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 48.
    2) To evaluate the safety and tolerability of MK-1439A q.d. compared with ATRIPLA? q.d. as measured by the proportion of subjects with neuropsychiatric adverse events in the following categories:
    -Dizziness
    -Sleep disorders and disturbances
    -Altered Sensorium
    1) Evaluar la actividad antirretroviral no inferior de MK-1439A 1 v/d en comparación con ATRIPLA 1 v/d medida por la proporción de sujetos que alcancen un ARN del VIH-1 < 50 copias/ml (cuantificado mediante la prueba del VIH-1 Abbott RealTime) en la semana 48.
    2) Evaluar la seguridad y la tolerabilidad de MK 1439A 1 v/d comparado con ATRIPLA? 1 v/d midiendo la proporción de sujetos que comuniquen acontecimientos adversos neuropsiquiátricos en las siguientes categorías:
    -Mareos
    -Trastornos y alteraciones del sueño
    -Sensorio alterado
    E.2.2Secondary objectives of the trial
    1) To evaluate the safety and tolerability of MK-1439A q.d. compared to ATRIPLA? q.d. as assessed by review of the accumulated safety data by Week 48 and Week 96.
    2) To evaluate the effect of MK-1439A q.d. compared to ATRIPLA? q.d. on fasting LDL-C as measured by the mean change from baseline at Week 48.
    3) To evaluate the effect of MK-1439A q.d. compared to ATRIPLA?q.d. on fasting non-HDL-C as measured by the mean change from baseline at Week 48.
    4) To evaluate the safety and tolerability of MK-1439A q.d. compared with ATRIPLA? q.d. as measured by the proportion of subjects with neuropsychiatric adverse events in the following categories:
    -Depression and suicide/self-injury
    -Psychosis and psychotic disorders
    (Read rest in the protocol)
    1) Evaluar la seguridad y tolerabilidad de MK 1439A 1 v/d en comparación con ATRIPLA? 1 v/d determinadas por los datos acumulados sobre seguridad en la semana 48 y la semana 96.
    2) Evaluar el efecto de MK 1439A 1 v/d en comparación con ATRIPLA? 1 v/d sobre el C LDL en ayunas medido por la variación media entre el momento basal y la semana 48.
    3) Evaluar el efecto de MK 1439A 1 v/d en comparación con ATRIPLA? 1 v/d sobre el C no HDL en ayunas medido por la variación media entre el momento basal y la semana 48.
    4) Evaluar la seguridad y la tolerabilidad de MK 1439A 1 v/d comparado con ATRIPLA?1 v/d midiendo la proporción de sujetos con acontecimientos adversos neuropsiquiátricos en las siguientes categorías:
    -Depresión y suicidio/autolesiones
    -Psicosis y trastornos psicóticos
    (Leer resto en el protocolo)
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Merck will conduct Future Biomedical Research on DNA (blood) specimens collected during this clinical trial. Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs, and/or to ensure that subjects receive the correct dose of the correct drug at the correct time.?
    Merck llevará a cabo investigaciones biomédicas futuras con las
    muestras obtenidas específicamente con estos fines durante este ensayo
    clínico.Estas investigaciones tendrán por objeto el análisis de
    biomarcadores para abordar aspectos nuevos que no se describen en
    otras partes del protocolo (como parte del ensayo principal) y solo se
    llevarán a cabo en muestras de los sujetos que hayan otorgado el
    consentimiento correspondiente. El objetivo de la obtención de muestras
    para investigaciones biomédicas futuras consiste en estudiar e identificar biomarcadores que proporcionen información a los científicos sobre las enfermedades y sus tratamientos. El objetivo último es utilizar tal información para desarrollar vacunas y fármacos más seguros y eficaces o para garantizar que los pacientes reciban la dosis correcta del fármaco o la vacuna adecuados en el momento preciso.
    E.3Principal inclusion criteria
    1. be at least 18 years of age on the day of signing the informed consent
    2. understand the study procedures and voluntarily agree to participate by giving written informed consent (or have a legal representative provide written informed consent) for the trial. The subject or his/her legal representative may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
    3. be HIV-1 positive as determined by a positive result on an enzyme-immunoassay, have screening plasma HIV-1 RNA (determined by the central laboratory) ?1000 copies/mL within 45 days prior to the treatment phase of this study, and have HIV treatment indicated based on physician assessment. Local treatment guidelines should be considered in the decision to initiate therapy.
    4. be naïve to antiretroviral therapy (ART) including investigational antiretroviral agents.
    5. have the following laboratory values at screening within 45 days prior to the treatment phase of this study:
    a. Alkaline phosphatase ? 3.0 x upper limit of normal
    b. AST (SGOT) and ALT (SGPT) ? 5.0 x upper limit of normal
    c. Hemoglobin ?9.0 g/dL (if female) or ?10.0 g/dL (if male).
    6. have a calculated creatinine clearance at the time of screening ? 50 mL/min, based on the Cockcroft-Gault equation which is as follows:
    For males: Clcr (mL/min) = (140-age) x weight (in kg)
    72 x serum creatinine (mg/dL)
    For females: Clcr (mL/min) = (140-age) x weight (in kg) x 0.85
    72 x serum creatinine (mg/dL)
    7. In the opinion of the investigator, be considered clinically stable with no signs or symptoms of active infection at the time of entry into the study (i.e., clinical status and all chronic medications should be unchanged for at least 2 weeks prior to the start of treatment in this study).
    (Read rest in the protocol)
    1. Tener al menos 18 años el día de la firma del consentimiento informado.
    2. Comprender los procedimientos del estudio y aceptar voluntariamente participar otorgando el consentimiento informado por escrito para el ensayo. El sujeto también podrá otorgar su consentimiento para investigaciones biomédicas futuras. No obstante, podrá participar en el ensayo principal sin necesidad de participar en las investigaciones biomédicas futuras.
    3. Estar infectado por el VIH 1, según lo determinado por un resultado positivo en un enzimoinmunoanálisis, presentar un ARN del VIH 1 en plasma ? 1.000 copias/ml durante la selección (determinado por el laboratorio central) en los 45 días previos a la fase de tratamiento de este estudio y tener indicación de tratamiento para el VIH de acuerdo con la evaluación del médico. En la decisión de iniciar el tratamiento deberán tenerse en cuenta las directrices de tratamiento locales.
    4. No haber recibido tratamiento antirretroviral (TAR) previamente, incluidos antirretrovirales experimentales.
    5. Tener los valores analíticos siguientes en el momento de la selección dentro de los 45 días previos al inicio de la fase de tratamiento de este estudio:
    a. Fosfatasa alcalina ? 3,0 veces el límite superior de la normalidad.
    b. AST (SGOT) y ALT (SGPT) ? 5,0 veces el límite superior de la normalidad.
    c. Hemoglobina ?9,0 g/dl (mujeres) o ?10,0 g/dl (varones).
    6. Presentar un aclaramiento de creatinina calculado en el momento de la selección ? 50 ml/min, de acuerdo con la ecuación de Cockcroft Gault, que es como sigue:
    Varones: Clcr (ml/min) = (140 edad) x peso (en kg)
    72 x creatinina sérica (mg/dl)
    Mujeres: Clcr (ml/min) = (140 edad) x peso (en kg) x 0,85
    72 x creatinina sérica (mg/dl)
    7. En opinión del investigador, el sujeto está clínicamente estable, sin signos o síntomas de infección activa, en el momento de entrada en el estudio (es decir, el estado clínico y los medicamentos crónicos no deberán haber cambiado, como mínimo, en las 2 semanas previas al comienzo del tratamiento en este estudio).
    (Leer resto en el protocolo)
    E.4Principal exclusion criteria
    1.has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject´s participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
    2.is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence. The nature and potential clinical context of the subject's illicit drug use, in relation to their exclusion from this trial, will be at the discretion of the Investigator.
    3.has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1, including, but not limited to, adefovir, tenofovir, entecavir, emtricitabine, or lamivudine.
    4.has documented or known resistance to study drugs including MK-1439, efavirenz, emtricitabine, lamivudine, and/or tenofovir, as defined below:
    a.Resistance to MK-1439 or efavirenz for the purpose of this study includes the following NNRTI mutations: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, P225H, F227C, F227L, F227V, M230L, M230I
    b.Resistance to emtricitabine, lamivudine and tenofovir includes the following mutations: K65R, M41L, T69S (insertion complex), Q151M, M184I, M184V, L210W, T215F, T215Y, K219E, K219Q, D67N, K70R and K70E.
    5.has participated in a study with an investigational compound/device within 30 days prior to signing informed consent or anticipates participating in such a study involving an investigational compound/device during the course of this study.
    6.has used systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study.
    Note: Short courses of corticosteroids (e.g., as for asthma exacerbation) will be allowed.
    7.requires or is anticipated to require any of the prohibited medications noted in the protocol.
    8.has significant hypersensitivity or other contraindication to any of the components of the study drugs as determined by the investigator.
    9.has a current (active) diagnosis of acute hepatitis due to any cause.
    10. has evidence of decompensated liver disease manifested by the presence of or a history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver diseases
    or
    has liver cirrhosis and a Child-Pugh Class C score or Pugh-Turcotte (CPT) score > 9
    11.is pregnant, breastfeeding, or expecting to conceive.
    12.is female and is expecting to donate eggs (at any time during the study) or is male and is expecting to donate sperm (at any time during the study).
    13.is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial.
    1. Tiene antecedentes o signos presentes de cualquier proceso, tratamiento, anomalía analítica u otra circunstancia que podría confundir los resultados del estudio o interferir en la participación del sujeto durante todo el estudio, por lo que no le conviene participar.
    2. En el momento de firmar el consentimiento informado, consume drogas o tiene antecedentes recientes de abuso o dependencia de drogas o alcohol. La naturaleza y el posible contexto clínico del consumo de drogas del sujeto, en relación con su exclusión de este estudio, se dejará a criterio del investigador.
    3.Ha sido tratado por una infección viral distinta del VIH 1, como hepatitis B, con un fármaco que es activo contra el VIH 1, entre otros, adefovir, tenofovir, entecavir, entecavir, emtricitabina o lamivudina.
    4. Tener resistencia documentada o conocida a los fármacos del estudio, incluidos MK 1439, efavirenz, emtricitabina, lamivudina y/o tenofovir, como se define a continuación:
    a. La resistencia a MK 1439 o efavirenz para los fines de este estudio incluye las siguientes mutaciones contra los ITINN: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, P225H, F227C, F227L, F227V, M230L y M230I.
    b. La resistencia a emtricitabina, lamivudina y tenofovir incluye las siguientes mutaciones: K65R, M41L, T69S (complejo de inserción) Q151M: M184I, M184V, L210W, T215F, T215Y, K219E, K219Q y K70E.
    5. Ha participado en un estudio con un compuesto/producto sanitario en investigación en los 30 días previos a la firma del consentimiento informado o prevé participar en el mismo durante este estudio.
    6. Ha recibido inmunomoduladores o tratamiento inmunodepresor sistémico en los 30 días previos al tratamiento de este estudio o se prevé que los necesite durante el estudio.
    Nota: Se permitirán los ciclos breves de corticoides (p. ej., por una exacerbación asmática).
    7. Requiere, o se prevé que requiera, cualquiera de los medicamentos prohibidos indicados en el protocolo
    8. Presenta hipersensibilidad significativa o cualquier otra contraindicación a alguno de los componentes de los fármacos del estudio, según la valoración del investigador.
    9. Se le ha diagnosticado de hepatitis aguda activa de cualquier etiología.
    10. Presenta indicios de hepatopatía descompensada, manifestada por la presencia o antecedentes de ascitis, hemorragia por varices esofágicas o gástricas, encefalopatía hepática u otros signos o síntomas de hepatopatía avanzada.
    o
    presenta cirrosis hepática y una puntuación de Child-Pugh de clase C o una puntuación de Pugh-Turcotte (CPT) > 9.
    11. Está embarazada, en período de lactancia o está planeando un embarazo.
    12. Es una mujer que tiene previsto donar óvulos en cualquier momento del estudio o es un varón que tiene previsto donar semen en cualquier momento del estudio.
    13. Es o tiene un familiar directo (por ejemplo, cónyuge, padre/madre o tutor legal, hermano o hijo) que forma parte del personal del centro de investigación o del promotor implicado directamente en este ensayo.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the proportion of subjects achieving HIV-1 RNA < 50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 48. The primary safety endpoint is the proportion of subjects with certain neuropsychiatric adverse events by Week 48 in the following categories: dizziness, sleep disorders and disturbances and altered sensorium.
    La variable principal de eficacia es la proporción que logró ARN VIH-1 <50 copias / ml (por el Abbott RealTime HIV-1 ensayo) en la semana 48. El objetivo primario de seguridad es la proporción de sujetos con ciertos eventos adversos neuropsiquiátricos en la semana 48 en las siguientes categorías: mareos, trastornos del sueño y alteraciones y alteración del sensorio.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Treatment week 48
    Semana de tratamiento 48
    E.5.2Secondary end point(s)
    1.Safety and tolerability by Week 48 and Week 96
    2.Fasting LDL-C as measured by the mean change from baseline at Week 48
    3.Fasting non-HDL-C as measured by the mean change from baseline at Week 48
    4.Proportion of subjects with neuropsychiatric AEs in the following categories by Week 48: depression and suicide/self-injury and psychosis and psychotic disorders.
    5.Proportion of subjects with at least one neuropsychiatric AE in any of the 5 categories of: dizziness, sleep disorders and disturbances, altered sensorium, depression and suicide/self-injury, and psychosis and psychotic disorders.
    6.Time to discontinuation from study due to an adverse experience
    7.Change from baseline in CD4 cell count at Week 48 and Week 96
    8.The proportion of subjects achieving HIV-1 RNA
    < 50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 96
    9.The proportion of subjects achieving HIV-1 RNA
    < 40 copies/mL (BLoQ) (by the Abbott RealTime HIV-1 Assay) at Week 48 and Week 96
    1. Seguridad y tolerabilidad en la semana 48 y la semana 96
    2. C LDL en ayunas medido por la variación media respecto al valor basal en la semana 48
    3. C no HDL en ayunas medido por la variación media respecto al valor basal en la semana 48
    4. Proporción de sujetos con AA neuropsiquiátricos en las siguientes categorías en la semana 48: Depresión y suicidio/autolesiones Y Psicosis y trastornos psicóticos
    5. Proporción de sujetos con al menos un AA neuropsiquiátrico en cualquiera de las siguientes cinco categorías: mareos, trastornos y alteraciones del sueño, sensorio alterado, depresión y suicidio/autolesiones y psicosis y trastornos psicóticos.
    6. Tiempo transcurrido hasta la suspensión del estudio debido a un acontecimiento adverso
    7. Variación con respecto al valor basal del recuento de linfocitos CD4 en las semanas 48 y 96
    8. Proporción de sujetos con un ARN del VIH 1 < 50 copias /ml (calculado mediante la prueba del VIH 1 Abbott RealTime) en la semana 96
    9. Proporción de sujetos que alcanzan un nivel del ARN del VIH 1 < 40 copias/ml (LIdC) (calculado mediante la prueba del VIH 1 Abbott RealTime) en la semana 48 y la semana 96
    E.5.2.1Timepoint(s) of evaluation of this end point
    Treatment Weeks 48 and 96
    Semanas de tratamiento 48 y 96
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA38
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Belgium
    Brazil
    Canada
    Chile
    Colombia
    Denmark
    Germany
    Guatemala
    Israel
    Korea, Republic of
    Mexico
    Netherlands
    New Zealand
    Peru
    Portugal
    Puerto Rico
    Russian Federation
    South Africa
    Spain
    Switzerland
    Taiwan
    Thailand
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last subject?s last study-related phone call or visit.
    última llamada telefónica o visita relacionada con el estudio del último paciente, para la realización del ensayo.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 675
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 5
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Only if legal representative can provide written informed consent
    Sólo si el representante legal puede dar su consentimiento informado por escrito
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state24
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 165
    F.4.2.2In the whole clinical trial 680
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There will be a mechanism for eligible study participants to continue treatment with MK-1439A after completing the study and without interruption, until it becomes locally available in the market. Subjects eligible for this mechanism will be those who have completed the last scheduled study visit, are considered by the investigator to have derived benefit from study participation, and for whom further treatment with MK1439A is considered clinically appropriate.
    Habrá un mecanismo para que los participantes del estu elegibles sigan recibiendo tratamie con MK 1439A tras finalizar el estu sin interrupción, hasta que se encuentre disponible en el mercado local. Los sujetos elegibles para este mecanismo serán aquéllos que hayan acudido a la última visita del estu programada, el IP considere que han recibido un beneficio como consecuencia de su participación en el estu para los cuales se considere clínicamente adecuado seguir recibiendo tratamie con MK1439A.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-08-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-08-04
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-09-06
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:39:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA